Compare Travere Therapeutics Inc. Common Stock (TVTX) vs Zscaler Inc (ZS) Price & Performance

Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.

The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.

Zscaler (ZS) trades at $228.66, up 1.28% with strong technical momentum and bullish moving averages. The company shows impressive revenue growth from $1.1B in 2022 to $2.67B in 2025, though remains unprofitable with a -1.88% net margin. Recent earnings beats and 79.6% analyst buy ratings support optimism, while the stock faces headwinds from executive turnover and negative cash flow projections for 2026.

ZS presents a growth-focused opportunity in cybersecurity with AI-driven bookings up 50% sequentially, but investors must weigh high valuations (P/S 10.79) against persistent profitability challenges and near-term execution risks following the chief revenue officer departure. The consensus price target of $222.83 suggests limited upside from current levels.